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Brief Reports
Optimal Tobramycin Dosage in Patients with
Cystic Fibrosis – Evidence for Predictability
Based on Previous Drug Monitoring
K. Bartel, T. Habash, S. Lugauer, H. Brmeier, B. Bwing, M. nsal, C. Schoerner, U. Heininger
Summary
A retrospective analysis of files of patients with cystic
fibrosis and pulmonary exacerbations was performed to
investigate whether an individual dosage of tobramycin
once established by serum level determination allows a
reliable prediction of the adequate dosage in a consecu-
tive exacerbation. All patients hospitalized ‡ 2 times
between May 1997 and September 1998 with pulmonary
exacerbation due to Pseudomonas aeruginosa infection
susceptible to tobramycin were included. The initial
dosage to tobramycin was 5 mg/kg body weight every
12 h followed by drug level determinations to establish
the optimal dose. In a consecutive exacerbation the same
dosage per kg body weight was used again and drug
level determinations were repeated. Sixteen patients (six
female = 38%) with a mean age of 24 years (median: 26
years, range: 9—33) were hospitalized for 49 pulmonary
exacerbations (2—6 per patient, mean: 3, median: 2.5).
During the first episode of tobramycin treatment in the
study period all trough levels were < 2 µg/ml (median:
0.6) and the peak levels were 7.1—16.9 µg/ml (median:
11.9). In four patients the peak level was > 12 µg/ml. In 28
consecutive episodes the dosage of tobramycin was
chosen based on optimal results of previous drug level
monitoring and in 27 instances (96%) the previously
established optimal dose was confirmed. In five consecu-
tive episodes the tobramycin dosage had been increased
erroneously and this resulted in abnormally high peak
levels in three cases. These findings suggest that a safe
and therapeutic tobramycin dosage in an individual
patient with cystic fibrosis is predictable based on a
previously established optimal dosage.
Introduction
Patients with late stage cystic fibrosis repeatedly suffer from
pulmonary exacerbations caused by Pseudomonas aerugi-
nosa infection of the lungs.The standard treatment of these
exacerbations is the i.v. application of aminoglycosides, such
as tobramycin, and betalactam antibiotics effective against
P. aeruginosa (e.g. ceftazidim, piperacillin). Because of the
different pharmacodynamics of antibiotics in patients with
cystic fibrosis as compared to healthy subjects (increased dis-
tribution volume per kg body weight and decreased serum
half-life) high doses of antibiotics have to be administered
for successful therapy [1]. Especially in the case of amino-
glycosides, serum levels need to be monitored during ther-
apy to guarantee correct dosage. Thus, lack of therapy due
to underdosage and harmful side effects, such as nephro-
toxicity and ototoxicity caused by overdosage, can be avoided
[2]. With progressive lung disease intervals between single
episodes of pulmonary exacerbation tend to decrease and
aminoglycosides need to be administered frequently. We
wondered, whether an individual dosage of tobramycin
once established by serum level determination allows a
reliable prediction of the adequate dosage in a consecutive
exacerbation.A retrospective analysis of patients’ files was
performed to answer this question.The results are the sub-
ject of this report.
Patients and Methods
Patients
All patients with cystic fibrosis included in this analysis were hos-
pitalized ‡ 1–2 times in our institution with pulmonary exacerba-
tion associated with growth of P. aeruginosa susceptible to to-
bramycin in the sputum between May 1997 and September 1998.
Each patient’s body weight was determined on admission to the
hospital.The initial dosage of tobramycin was 5 mg/kg body weight
every 12 h unless the patient had received treatment with to-
bramycin previously and drug level determinations had estab-
lished the optimal dosage. In this case the same dosage per kg
body weight was used again.
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Methods
As part of our standard procedures, tobramycin was administered
over 30 min intravenously (doses < 80 mg in 50 ml 0.9% NaCl; doses
‡ 80 mg in 100 ml 0.9% NaCl) at 12 h intervals and trough and peak
drug levels were measured on day 3 of treatment before and after
the sixth dose, respectively (TDx-Analyzer,Abbott Diagnostics,Wies-
baden, Germany). In addition to tobramycin, other antibiotics
were given depending on the results of sputum cultures and bac-
terial resistance patterns; the interval between application of two
different antibiotics was at least 2 h. On admittance to the hospi-
tal, serum creatinine and urea levels were determined in addition
to a number of other routine tests, including full blood count, c-re-
active protein levels and others.These laboratory tests were repeated
two to three times per week for the duration of therapy. Blood for
tobramycin trough level determination was taken before admin-
istration of the sixth dose and blood for determination of the peak
level was collected 30–60 min after the end of the infusion of the
sixth dose. According to the manufacturer’s instruction, a to-
bramycin trough level of < 2 µg/ml and a peak level of 5–12 µg/ml
were considered optimal (variation coefficient of the method:< 6%).
Data analysis
For each patient each individual exacerbation during the study pe-
riod was analyzed for dosage of tobramycin per kg body weight,
trough and peak drug level determinations and time differences be-
tween consecutive exacerbations. If an individual dosage resulted
in optimal peak and trough levels, as defined above, and the same
dosage of tobramycin (per kg body weight) was used again for treat-
ment of the next exacerbation, again resulting in optimal drug lev-
els, the patient’s individual dosage was considered “reliable.” Bra-
vais-Pearson correlation coefficient was used for 2-tailed correla-
tion analysis between tobramycin dosage and patient’s weight.
Results
Between May 1, 1997, and September 30, 1998, a total of 16
(six female = 38%) patients fulfilled the inclusion criteria.Their
mean age was 24 years (median:26 years, range:9–33).There
were 49 episodes of pulmonary exacerbation (2–6 per patient,
mean: 3, median: 2.5) for analysis.The interval between two
consecutive exacerbations in a patient varied from 1–17
months (median: 6 months).
The dosage of tobramycin used for treatment of an exac-
erbation varied between 2 3 3.0 mg/kg body weight/day and
2 3 9.0 mg/kg body weight/day (median: 2 3 4.7). There was
no clinical evidence of serious side effects during treatment
of any episode nor was there an increase of creatinine or urea
serum levels noted at any time.Furthermore, trough levels of
tobramycin were always below 2 µg/ml.
In Figure 1 the correlation between total body weight
and tobramycin dosage (in mg/kg body weight) is demon-
strated. For this specific analysis data from patients who were
hospitalized only once during the study period were in-
cluded to increase the power. As can be seen, there was an
inverse correlation between body weight and individual
tobramycin dosage (r = – 0.69; p < 0.001).
When the first episode of tobramycin treatment in the
16 patients was analyzed, the following results were ob-
tained: All trough levels were < 2 µg/ml (median: 0.6). The
peak levels were 7.1–16.9 µg/ml (median: 11.9) and in four
patients (25%) the peak level was > 12 µg/ml, leading to a
dose reduction followed by another drug level determina-
tion with the sixth dose after the change in three of four
patients (Table 1).
An analysis of 33 consecutive episodes in these 16 pa-
tients revealed the following findings:All trough levels were
< 2 µg/ml (median: 0.4).The peak levels were 5.6–15.0 µg/ml
(median:11.5) and in four episodes (12%) the peak level was
>12 µg/ml, leading to a dose reduction followed by another
Figure 1
Correlation of body weight (kilogram) and dosage of tobramycin
(in mg per kg body weight/24 h) in patients with cystic fibrosis
and pulmonary exacerbation.
Patient Age Dosage 1 Trough level Peak level Dosage 2 Trough level Peak level
(years) (mg/kg) (µg/ml) (µg/ml) (mg/kg) (µg/ml) (µg/ml)
1 27 2 x 4.5 0.6 16.9 2 x 4.1 0.7 14.2
2 25 2 x 3.8 0.4 16.1 2 x 3.3 0.5 5.0
3 28 2 x 3.6 0.6 13.3 2 x 3.2 0.9 9.0
4 30 2 x 5.1 0.4 14.4 2 x 4.6 n.d. n.d.
n.d. = not done.
Table 1
Tobramycin dosage and drug level determinations in patients with abnormally high peak levels during the first episode of tobramycin treat-
ment in this study.
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drug level determination with the sixth dose after the change
in three of four patients (Table 2).
In these 29 consecutive episodes, where peak and trough
level determinations had revealed “optimal dosage,” the
dose per kg body weight was identical to that used for treat-
ment in 27 cases at the end of the previous episode. In two
patients an unjustified change of dosage had been per-
formed for treatment of the consecutive episode but the peak
tobramycin level remained in the optimal range.
In contrast, in three of the four consecutive episodes
with abnormally high peak levels (patients 3,4 and 5 in Table
2), the tobramycin dosage had been increased for unknown
reasons compared to the previous dosage considered to be
optimal (patient 5) or to a previous drug level analysis which
had already indicated that the dosage was too high (patients
3 and 4,Tables 1 and 2). In patient six an abnormally high peak
level was measured,despite the fact that the same dosage had
resulted in an optimal peak level 11 months before.
Overall, in 28 episodes of pulmonary exacerbation the
dosage of tobramycin was chosen based on optimal results
of previous drug level monitoring and in 27 instances (96%)
determination of tobramycin trough and peak levels confirmed
the previously established optimal dose.
Discussion
Aminoglycosides are an essential part of successful treatment
of pulmonary exacerbations in patients with cystic fibrosis
[3].While short dosing intervals of tobramycin (every 6–8 h)
had been recommended until approximately 10 years ago
[4, 5], it has been shown that dosing intervals of 12 h or even
24 h are advantegous compared to traditional 8 h intervals
[2, 6]: Lower trough levels and higher peak levels can be ob-
tained with lower total amounts of tobramycin with prolonged
dosing intervals compared to an 8 h dosing interval. To
guarantee success of therapy and to avoid toxic side ef-
fects, the serum levels of aminoglycosides before (trough)
and after (peak) application in the steady state phase are rec-
ommended. The goal is to achieve trough levels of tobra-
mycin below 2 µg/ml and peak levels in the upper part
of the recommended range (i.e. > 8 µg/ml) [7].Although dif-
ferent ways to establish the optimal dosage of aminoglyco-
sides in patients with cystic fibrosis have been suggested, in-
cluding calculations based on body surface [5], lean body mass
[8] and body weight [9], the general consensus has been that
each new episode requires determination of trough and
peak aminoglycoside levels.
The findings in the present study, however, suggest that
a once established optimal dosage of tobramycin in an in-
dividual patient might be re-used for consecutive treat-
ments up to 17 months later, thus saving time, effort and
money involved with repeated drug level monitoring.As we
demonstrated, in 27 of 28 later episodes monitoring of
tobramycin trough and peak levels confirmed the findings
obtained with the same dosage during the previous treat-
ment. In the only instance where this was not the case (pa-
tient 6 in Table 2), reduction of the dosage resulted in an un-
usually prominent decrease of the peak level, suggesting an
error during specimen sampling or in the laboratory process
when the initial peak level was measured. In two patients
(patients 3 and 4 in Tables 1 and 2), the abnormally high peak
level measured during a consecutive course of tobramycin
treatment was based on not taking a previous result of a
tobramycin level assay into account, which had already in-
dicated that the individual dosage was too high. It has re-
cently been discussed that patients with cystic fibrosis and
pulmonary colonization with P. aeruginosa be treated with
i.v. antibiotics every 3–4 months regardless of signs of acute
exacerbation (“aggressive therapy”) [10]. Although this
strategy has not yet been universally accepted (and not
been practiced in our institution), in light of such a new ten-
dency, our findings suggest that results from a previous
tobramycin serum level determination can serve as a reli-
able dosage guideline during each new course of antibiotic
treatment, provided that no major changes in medical con-
ditions (e.g. renal function) have occured in the meantime.
However, for the time being it is still wise to confirm the
right dosage by drug level determination.
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